Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained~* Subjects diagnosed with type 2 diabetes and treated with either diet and exercise alone, metformin, sulphonylurea, glitazone as single agent therapy or a combination of the previously mentioned compounds~* HbA1c 7.0-10.0% (both inclusive)~* Body Mass Index (BMI) at least 27.0 kg/m\^2~* Stable body weight~* Preceding failed dietary effort~Exclusion Criteria:~* Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors or insulin within the last 3 months~* Known proliferative retinopathy or maculopathy~* History of acute or chronic pancreatitis~* Obesity induced by drug treatment~* Use of approved weight lowering pharmacotherapy~* Previous surgical treatment of obesity~* History of major depressive disorder or suicide attempt~* Uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)~* Screening calcitonin of 50 ng/L or above~* Familial or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)~* Personal history of non-familial medullary thyroid carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lira 3.0 mg (Type: EXPERIMENTAL): None
- Lira 1.8 mg (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).